150
Participants
Start Date
February 11, 2021
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2025
Uterine curettage
Manual or electric vacuum aspiration under ultrasound guidance.
Chemotherapy
conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
NOT_YET_RECRUITING
Paulista State University UNESP, Botucatu
RECRUITING
Campinas State University UNICAMP, Campinas
RECRUITING
University of Caxias do Sul, Caxias do Sul
RECRUITING
Federal University of Ceará, Ceará
RECRUITING
Medical School of Santa Casa da Misericórdia de Porto Alegre, Porto Alegre
RECRUITING
Maternidade Escola da Universidade Federal do Rio de Janeiro, Rio de Janeiro
RECRUITING
Federal University of São Paulo UNIFESP, São Paulo
Maternidade Escola da Universidade Federal do Rio de Janeiro
UNKNOWN
Universidade Federal do Rio de Janeiro
OTHER
Federal University of Ceará
UNKNOWN
Federal University of São Paulo UNIFESP
UNKNOWN
Campinas State University UNICAMP
UNKNOWN
Paulista State University UNESP BOTUCATU
UNKNOWN
Medical School of Santa Casa da Misericórdia de Porto Alegr
UNKNOWN
University of Caxias do Sul
UNKNOWN
Brigham and Women's Hospital
OTHER